These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC. Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617 [Abstract] [Full Text] [Related]
3. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Arthritis Rheum; 2009 Aug; 60(8):2272-83. PubMed ID: 19644849 [Abstract] [Full Text] [Related]
5. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study. Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K. Mod Rheumatol; 2016 Aug; 26(1):24-8. PubMed ID: 26140464 [Abstract] [Full Text] [Related]
8. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Tanaka Y, Mimori T, Yamanaka H, Sunaga N, Morita K, Kimura J, Takeuchi T. Mod Rheumatol; 2020 May; 30(3):424-433. PubMed ID: 31267801 [Abstract] [Full Text] [Related]
14. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS, TEAR Investigators. Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468 [Abstract] [Full Text] [Related]
15. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Müller RB, von Kempis J, Haile SR, Schiff MH. Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697 [Abstract] [Full Text] [Related]
16. Six-month flare risk after discontinuing long-term methotrexate treatment in patients having rheumatoid arthritis with low disease activity. Lee JS, Oh JS, Hong S, Kim YG, Lee CK, Yoo B. Int J Rheum Dis; 2020 Aug; 23(8):1076-1081. PubMed ID: 33021334 [Abstract] [Full Text] [Related]
17. Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis. Smolen JS, Pedersen R, Jones H, Mahgoub E, Marshall L. Rheumatology (Oxford); 2020 Jan 01; 59(1):153-164. PubMed ID: 31257453 [Abstract] [Full Text] [Related]
18. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors. Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, Geborek P. Arthritis Rheum; 2011 Dec 01; 63(12):3723-32. PubMed ID: 21834061 [Abstract] [Full Text] [Related]